scholarly journals Erratum: Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 39 (5) ◽  
pp. 419
Author(s):  
Xiang Xiao ◽  
Huan Deng ◽  
Mumba Mulutula Chilufya ◽  
Yizhen Lv ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Symptom Index ◽  
Bladder Pain ◽  
Acid Perfusion

Paper link corrected: https://bonoi.org/index.php/si/article/view/636 It has been brought to authors attention that there is a missing part in “Materials and Methods” of the Systematic Review article by Xiao et al., entitled “Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis” in the Volume 39, No. 4 of Science Insights (pp.363-373). The missing part of the “Materials and Methods” is as below: Population: Patients with IC/BPS.Intervention: All patients underwent intravesical HA and/or CS treatment regimen.Comparison: Improvement in symptoms pre-treatment and post-treatment or other treatment regimen.Outcome: The primary outcome was the change in visual analogue scale (VAS) for pain symptom from baseline to the follow-up period; secondary outcomes were the changes in total scores of the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), storage symptoms including frequency and urgency, and bladder capacity.

scholarly journals Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 39 (4) ◽  
pp. 361-373
Author(s):  
Xiang Xiao ◽  
Huan Deng ◽  
Mumba Mulutula Chilufya ◽  
Yizhen Lv ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Cochrane Library ◽  
Bladder Pain ◽  
Effect Model ◽  
Significant Difference

Currently, no suitable delivery methods are available for the drugs to interstitial cystitis/ bladder pain syndrome (IC/BPS). Herein we systematically evaluated the therapeutic effects of intravesical infusion of hyaluronic acid (HA) and chondroitin sulfate (CS) in patients with IC/BPS. This study includes randomized controlled trials (RCT) and self-controlled studies of IC/BPS patients treated with HA, CS, or both. English databases like PubMed, Cochrane Library, Embase, and Medline were searched until up to January 31, 2021. Information was extracted based on the inclusion and exclusion criteria, and then meta-analysis was performed. Sixteen studies including 491 patients were included and analyzed. The responsive rate of treatment was 91.24%. In 3 RCTs, the analogue scale (VAS) for pain on fix-effect model was [mean difference, MD -0.57 (95%CI, -1.55, -0.41)]. A significant improvement on random-effect model was [MD -2.78 (95%CI, -3.48, -2.07)] in 13 self-controlled studies. Outcomes on O’Leary-Sant Interstitial Cystitis Symptom Index, Problem Index, frequency, urgency, and bladder capacity were also significantly improved. Subgroup analysis showed significant difference between HA, CS, and the combination, and the perfusion of HA was more effective (Z = 29.97, P < 0.01). Also, different follow-up times after last treatment showed significant difference (Z = 7.69, P < 0.01). It can be beneficial for IC/BPS patients who have not responded to conventional treatments.

scholarly journals THE EFFECTIVENESS OF TNF-Α INHIBITOR THERAPY IN BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 28 (2) ◽  
pp. 194-201
Author(s):  
Ahmad Kholis ◽  
Soetojo ◽  
Wahjoe Djatisoesanto
Keyword(s):  
Systematic Review ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Response Assessment ◽  
Bladder Pain Syndrome ◽  
Inhibitor Therapy ◽  
Global Response ◽  
Bladder Pain ◽  
Tnf Α

Objective: To evaluate the effectiveness of TNF-α inhibitor therapy in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) patients compared to placebo, assessed using Global Response Assessment (GRA). Material & Methods: A systematic review and meta-analysis. Subjects were patients with moderate to severe diagnosis of BPS/IC who were given TNF-α inhibitor versus placebo, with the Global Response Assessment (GRA) (patient-reported self-reported BPS/IC treatment response scale). A systematic literature search was carried out on the English databases PubMed/MEDLINE and Science  Direct, published until September 2020. Data were extracted independently and assessed the bias and quality of each selected article. Results: Initially there were 124 studies. After further selection, 2 RCT studies were included in the criteria for this study. The number of samples obtained was 85 patients. There is 1 study that used 400 mg of certolizumab pegol subcutaneously and 1 study used adalimumab 80 mg subcutaneously and followed by 40 mg subcutaneously for 2 weeks. Both studies had statistically low heterogeneity with I2 = 0% (P = 0.34), so fixed effect statistical model was used to determine the result. Furthermore, there was no significant difference (P = 0.32) between the number of GRA responders from the TNF-α inhibitor and placebo therapy groups, with odds ratio of 1.61 (CI = 0.65-4.00). Conclusion: TNF-α inhibitor therapy did not increase GRA responders when compared to placebo.

scholarly journals Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome

2016 ◽  
Vol 39 (4) ◽  
pp. 1618-1625 ◽  
Author(s):  
Jung-Soo Pyo ◽  
Won Jin Cho
Keyword(s):  
Systematic Review ◽  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Urine Volume ◽  
Painful Bladder Syndrome ◽  
Pain Symptom ◽  
Bladder Pain ◽  
Painful Bladder

Background/Aims: To assess the efficacy of intravesical hyaluronic acid (HA) and HA/chondroitin sulfate (CS) instillation in patients with interstitial cystitis/painful bladder syndrome by systematic review and meta-analysis. Methods: A systematic literature search was performed using the keywords: ‘interstitial cystitis' or ‘painful bladder syndrome' or ‘bladder pain syndrome' and ‘hyaluronic acid', up to March 31, 2016. The primary outcome was visual analogue scale related pain symptom (VAS). Secondary outcomes were the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), frequency, nocturia, bladder volume, and voided urine volume. Results: Ten articles involving 390 patients were retrieved and assessed in analysis. A significant improvement in mean VAS on fixed-effect and random-effect models (mean difference [MD] -3.654, 95% confidence interval [CI] -3.814 to -3.495, and MD -3.206, 95% CI -4.156 to -2.257, respectively) was found. Significant improvements were found in the ICSI (MD -3.223, 95% CI -4.132 to -2.315) and ICPI (MD -2.941, 95% CI -3.767 to -2.116). Similarly, the other outcomes were significantly improved. Conclusion: Intravesical HA and HA/CS instillation improved pain symptom, quality of life, and other outcomes and could be included as therapeutic modality of interstitial cystitis/painful bladder syndrome.

Sign in / Sign up

Export Citation Format

Share Document